热搜词：

CN

  • CN
  • EN

注册

产品中心 抗体 功能性抗体

Invivo Rat anti-Mouse CD276 Recombinant mAb

CD276 antigen,B7 homolog 3 (B7-H3),Costimulatory molecule,B7h3

货号： S0B1361

Datasheet COA
  • 价格： ￥700
  • 规格：
  • 数量：
斯达特大包装询价 大包装询价

产品介绍 评论(0)

产品规格

  • 宿主来源

    Rat

  • 抗原名称

    Mouse CD276

  • 分子别名

    CD276 antigen; B7 homolog 3 (B7-H3); Costimulatory molecule; B7h3

  • 细胞定位

    Membrane

  • Accession

    Q8VE98

  • 克隆号

    S-R633

  • 抗体类型

    Rat mAb

  • 抗体同种型

    Rat IgG1,k

  • 应用

    in vivo B7-H3 blockade

  • 反应种属 ?

    Ms

  • 纯化方式

    Protein G

  • 浓度

    5 mg/ml

  • 内毒素含量

    <2EU/mg

  • 标记

    Unconjugated

  • 性状

    Liquid

  • 缓冲体系

    PBS pH7.4, containing no preservative

  • 储存条件

    2 to 8 °C for 2 weeks under sterile conditions;

    -20 °C for 3 months under sterile conditions;

    -80 °C for 24 months under sterile conditions.

    Please avoid repeated freeze-thaw cycles.

  • 稀释度

    [{"application": "ELISA", "dilution": "", "species": ""}, {"application": "Sandwich ELISA", "dilution": "", "species": ""}, {"application": "CLIA", "dilution": "", "species": ""}, {"application": "Lateral Flow", "dilution": "", "species": ""}, {"application": "Dot Blot", "dilution": "", "species": ""}, {"application": "WB", "dilution": "", "species": ""}, {"application": "IP", "dilution": "", "species": ""}, {"application": "IHC-P", "dilution": "", "species": ""}, {"application": "ICC", "dilution": "", "species": ""}, {"application": "IF", "dilution": "", "species": ""}, {"application": "ICFCM", "dilution": "", "species": ""}, {"application": "FCM", "dilution": "", "species": ""}, {"application": "mIHC", "dilution": "", "species": ""}]
背景介绍

  • CD276 (B7-H3) is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.

    评论(0)